NCT07643012
Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer
Recruiting
NAAges 18–90InterventionalTreatmentRutgers, The State University of New JerseyInvestigator-initiated
~30 participants
Updated 2026-07-06 on ClinicalTrials.gov
What's tested:MR-guided adaptive pelvic intensity-modulated radiation therapy (IMRT)
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Acute Grade ≥2 Gastrointestinal and Genitourinary Toxicity
Measured over Within 90 days after completion of treatment
Conditions
Where it's being run
1 sites across 1 statesNew Jersey1
Study leadership
- Lara M Hathout · PRINCIPAL_INVESTIGATOR · Rutgers University - Cancer Institute
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of Acute Grade ≥2 Gastrointestinal and Genitourinary ToxicityWithin 90 days after completion of treatment
Defined as the number and proportion of participants experiencing grade ≥2 acute gastrointestinal or genitourinary treatment-related adverse events occurring within 90 days after completion of MR-guided adaptive pelvic IMRT, as assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0, a standardized grading system for adverse events ranging from Grade 1 (mild) to Grade 5 (death related to adverse event)